Ameriprise
AVXL icon

Ameriprise’s Anavex Life Sciences AVXL Stock Holding History

Ameriprise’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Sell
59,095
-15,278
-21% -$45.2K ﹤0.01% 3989
2026
Q1 		$228K Buy
74,373
+5,848
+9% +$25.3K ﹤0.01% 3837
2025
Q4 		$244K Sell
68,525
-17,270
-20% -$106K ﹤0.01% 3867
2025
Q3 		$764K Sell
85,795
-195
-0.2% -$1.98K ﹤0.01% 3477
2025
Q2 		$793K Buy
85,990
+1,233
+1% +$10.5K ﹤0.01% 3360
2025
Q1 		$727K Buy
84,757
+17,947
+27% +$169K ﹤0.01% 3345
2024
Q4 		$718K Buy
66,810
+3,243
+5% +$24.9K ﹤0.01% 3386
2024
Q3 		$361K Buy
63,567
+85
+0.1% +$490 ﹤0.01% 3593
2024
Q2 		$268K Sell
63,482
-730
-1% -$2.95K ﹤0.01% 3619
2024
Q1 		$327K Buy
64,212
+9,560
+17% +$53.8K ﹤0.01% 3559
2023
Q4 		$509K Buy
54,652
+18,277
+50% +$126K ﹤0.01% 3444
2023
Q3 		$238K Buy
36,375
+2,914
+9% +$23.2K ﹤0.01% 3648
2023
Q2 		$272K Sell
33,461
-15
-0% -$129 ﹤0.01% 3638
2023
Q1 		$287K Sell
33,476
-174
-0.5% -$1.74K ﹤0.01% 3628
2022
Q4 		$312K Buy
33,650
+13,895
+70% +$148K ﹤0.01% 3574
2022
Q3 		$203K Buy
19,755
+2,350
+14% +$24.8K ﹤0.01% 3703
2022
Q2 		$174K Buy
17,405
+300
+2% +$2.84K ﹤0.01% 3705
2022
Q1 		$211K Sell
17,105
-5,860
-26% -$72.1K ﹤0.01% 3745
2021
Q4 		$398K Sell
22,965
-13,000
-36% -$247K ﹤0.01% 3590
2021
Q3 		$645K Sell
35,965
-26,195
-42% -$521K ﹤0.01% 3317
2021
Q2 		$1.42M Sell
62,160
-30,965
-33% -$459K ﹤0.01% 3063
2021
Q1 		$1.39M Buy
93,125
+24,725
+36% +$270K ﹤0.01% 2997
2020
Q4 		$369K Buy
68,400
+35,645
+109% +$188K ﹤0.01% 3435
2020
Q3 		$149K Buy
32,755
+17,685
+117% +$76.1K ﹤0.01% 3596
2020
Q2 		$74K Sell
15,070
-1,735
-10% -$6.56K ﹤0.01% 3602
2020
Q1 		$53K Sell
16,805
-4,200
-20% -$14.6K ﹤0.01% 3579
2019
Q4 		$54K Buy
21,005
+5,005
+31% +$13.1K ﹤0.01% 3669
2019
Q3 		$19K Buy
+16,000
New +$46.2K ﹤0.01% 3685

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ameriprise's AVXL Position: Q2 2026 in Review

Ameriprise reduced its Anavex Life Sciences (AVXL) stake by 21% in Q2 2026, selling an estimated $45.2K and leaving 59,095 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #3989.

Ameriprise first reported a position in AVXL in Q3 2019 and has held it in 28 quarters since. The position peaked at $1.42M in Q2 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Ameriprise held 59,095 shares of Anavex Life Sciences worth $153K as of Q2 2026.
  • Ameriprise sold 15,278 Anavex Life Sciences shares in Q2 2026, an estimated $45.2K.
  • Anavex Life Sciences made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3989 holding.
  • Ameriprise first reported a position in Anavex Life Sciences in Q3 2019 and has held it in 28 quarters since.
  • Ameriprise's Anavex Life Sciences position peaked at $1.42M in Q2 2021.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.